Glaukos has announced the launch of EpioxaCareConnect, a patient support program designed to simplify access to Epioxa cross-linking treatment and guide patients throughout their care journey.
The FDA approved Epioxa HD / Epioxa in October 2025 as the first and only epithelium-on, oxygen-enriched corneal cross-linking treatment for keratoconus.
The new initiative aims to address common barriers to treatment by offering a centralized resource for access, reimbursement, and financial support. Through EpioxaCareConnect, patients and providers can receive assistance with benefit investigations, prior authorizations, appeals, and affordability programs—areas that often delay or complicate care.
A key feature of the program is personalized support. Each enrolled patient is paired with a dedicated Patient Access Liaison (PAL) who provides one-on-one, non-medical guidance. PALs help patients navigate insurance processes, answer logistical questions, and coordinate next steps, including follow-up care such as second-eye treatment when needed.
EpioxaCareConnect is structured around several core components:
Access and Reimbursement Support: The program conducts benefit investigations, outlines prior authorization requirements, and estimates patient out-of-pocket costs. It also determines eligibility for financial assistance and supports providers with pre-determinations, prior authorizations, and peer-to-peer reviews.
Specialty Pharmacy Coordination: Healthcare providers can submit Epioxa prescriptions directly through the program. When permitted by payers, EpioxaCareConnect works with specialty pharmacies to facilitate prescription fulfillment and administer financial assistance.
Dedicated Patient Support: Through the PAL team, patients receive ongoing guidance from enrollment through recovery. PALs remain engaged beyond the initial procedure to help ensure continuity of care and a smooth treatment experience.
Financial Assistance Programs: Eligible commercially insured patients may benefit from the Epioxa Copay Program, which can reduce out-of-pocket costs to as little as $0 for both the medication and the cross-linking procedure. Additionally, Glaukos offers a Patient Assistance Program (PAP) for qualifying uninsured or underinsured U.S. residents.
Additional tools are available at www.Epioxa.com, including enrollment forms, billing and coding guides, payer policy information, and educational materials to help patients better understand insurance coverage and financial options.
